Latest On TherapeuticsMD, Inc (TXMD):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-23 18:47 EST | News | TherapeuticsMD: From Fallen And Forgotten To Cash Cow | N/A |  |
| 2023-05-16 05:29 EST | News | Therapeutics MD GAAP EPS of -$0.24 beats by $0.87 | N/A | |
| 2023-04-10 13:04 EST | News | Therapeutics MD GAAP EPS of -$0.12 | N/A | |
| 2023-01-19 00:02 EST | News | TherapeuticsMD ends agreement with interim CFO, but will stay on in consulting role | N/A | |
| 2022-12-05 15:42 EST | News | TherapeuticsMD enters agreements to license products to Mayne Pharma | N/A | |
About TherapeuticsMD, Inc (TXMD):
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; and TX-007HR and TX-008HR, which are transdermal patch product candidates. The company's clinical development product is TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins unde read more...r the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription prenatal vitamin and hormone therapy drug products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
General
- Name TherapeuticsMD, Inc
- Symbol TXMD
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- Full Time Employees 400
- Last Split Factor1:100
- Last Split Date2011-10-03
- Fiscal Year EndDecember
- IPO Date2003-12-11
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryPharmaceuticals
- Gic SubIndustryPharmaceuticals
- Web URLhttp://www.therapeuticsmd.com
Valuation
- Price/Sales (Trailing 12 Mt.) 6.8
- Price/Book (Most Recent Quarter) 40.75
- Enterprise Value Revenue 12.16
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate -$0.37
- Next Year EPS Estimate -$0.11
- Next Quarter EPS Estimate -$0.10
- Profit Margin -283%
- Operating Margin -240%
- Return on Assets -43%
- Revenue 64.87 million
- Earnings Per Share -$0.72
- Revenue Per Share $0.24
- Gross Profit 48.9 million
- Quarterly Earnings Growth 42%
Highlights
- Market Capitalization 581.74 million
- EBITDA -151833168
- PE Ratio -3.57
- PEG Ratio -0.73
- Analyst Target Price $6.17
- Book Value Per Share $0.03
Share Statistics
- Shares Outstanding 387.83 million
- Shares Float 361.63 million
- % Held by Insiders 1122%
- % Held by Institutions 54.05%
- Shares Short 55.74 million
- Shares Short Prior Month 72.67 million
- Short Ratio 2.59
- Short % of Float 15%
- Short % of Shares Outstanding 14%
Technicals
- Beta 1.98
- 52 Week High $2.65
- 52 Week Low $0.85
- 50 Day Moving Average 1.68
- 200 Day Moving Average 1.46
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
TherapeuticsMD, Inc (TXMD) Dividend Calendar:
TherapeuticsMD, Inc (TXMD) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
TherapeuticsMD, Inc (TXMD) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
TherapeuticsMD, Inc (TXMD) Chart:
TherapeuticsMD, Inc (TXMD) News:
Below you will find a list of latest news for TherapeuticsMD, Inc (TXMD) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
TherapeuticsMD, Inc (TXMD) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest TXMD Trades:
TherapeuticsMD, Inc (TXMD) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-09-14 | 8-K (Current report) | |
| 2020-08-14 | D (Notice of Exempt Offering of Securities) | |
| 2020-08-07 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-08-07 | S-8 (Securities to be offered to employees in employee benefit plans) | |
| 2020-08-07 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-07 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-08-07 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-08-06 | 8-K (Current report) | |
| 2020-06-23 | 8-K (Current report) | |
| 2020-06-23 | 8-K (Current report) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-19 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-06-18 | 8-K (Current report) | |
TherapeuticsMD, Inc (TXMD) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of TherapeuticsMD, Inc (TXMD). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1122%
Institutional Ownership: 5405%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-06-09 | Cooper C. Collins | Director | Buy | 47,500.00 | 1.45 | 68,875.00 | 140,000.00 | |
| 2020-06-09 | Robert G Finizio | CEO | Buy | 21,000.00 | 1.41 | 29,610.00 | 18,376,964.00 | |
| 2020-06-09 | Robert G Finizio | CEO | Buy | 25,000.00 | 1.47 | 36,750.00 | 18,401,964.00 | |
| 2020-06-08 | Cooper C. Collins | Director | Buy | 26,500.00 | 1.45 | 38,425.00 | 92,500.00 | |
| 2020-06-05 | Robert G Finizio | CEO | Buy | 10,000.00 | 1.16 | 11,600.00 | 18,335,964.00 | |
| 2020-06-05 | Robert G Finizio | CEO | Buy | 20,000.00 | 1.15 | 23,000.00 | 18,355,964.00 | |
| 2020-06-04 | PAUL BISARO | Director | Buy | 50,000.00 | 1.14 | 57,000.00 | 50,000.00 | |
| 2020-06-04 | Tommy G Thompson | Director | Buy | 8,700.00 | 1.13 | 9,831.00 | 699,600.00 | |
| 2020-02-03 | Mitchell Krassan | Chief Strategy Officer | Sell | 300,000.00 | 2.26 | 676,920.00 | 0.00 | |
| 2020-02-03 | Mitchell Krassan | Chief Strategy Officer | Buy | 105,703.00 | 0.19 | 19,808.74 | 105,703.00 | |
| 2020-02-03 | Mitchell Krassan | Chief Strategy Officer | Buy | 194,297.00 | 0.20 | 39,578.30 | 300,000.00 | |
| 2019-10-25 | John C.K. IV Milligan | President/Secretary | Buy | 72,000.00 | 2.75 | 198,000.00 | 1,544,419.00 | |
| 2019-10-25 | Robert G Finizio | CEO | Buy | 72,000.00 | 2.75 | 198,000.00 | 18,325,964.00 | |
| 2019-10-25 | Brian Bernick | Director | Buy | 36,000.00 | 2.75 | 99,000.00 | 98,000.00 | |
| 2019-08-23 | Angus C. Russell | Director | Buy | 10,000.00 | 2.77 | 27,700.00 | 93,500.00 | |
| 2019-08-20 | Robert G Finizio | CEO | Buy | 35,000.00 | 2.74 | 95,900.00 | 18,253,964.00 | |
| 2019-08-16 | John C.K. IV Milligan | President/Secretary | Buy | 10,000.00 | 2.93 | 29,300.00 | 3,582,373.00 | |
| 2019-08-15 | Angus C. Russell | Director | Buy | 10,000.00 | 2.99 | 29,900.00 | 83,500.00 | |
| 2019-08-14 | Angus C. Russell | Director | Buy | 25,000.00 | 2.76 | 69,000.00 | 73,500.00 | |
| 2019-08-12 | Jane F Barlow | Director | Buy | 3,144.00 | 3.18 | 9,997.92 | 3,144.00 | |